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Background: Besides being a preferential site of early metastasis, the sentinel lymph node (SLN) is also a privileged
site of T-cell priming, and may thus be an appropriate target for investigating cell types involved in antitumor
immune reactions.
Methods: In this retrospective study we determined the prevalence of OX40+ activated T lymphocytes, FOXP3+
(forkhead box P3) regulatory T cells, DC-LAMP+ (dendritic cell-lysosomal associated membrane protein) mature
dendritic cells (DCs) and CD123+ plasmacytoid DCs by immunohistochemistry in 100 SLNs from 60 melanoma
patients. Density values of each cell type in SLNs were compared to those in non-sentinel nodes obtained from
block dissections (n = 37), and analyzed with regard to associations with clinicopathological parameters and disease
outcome.
Results: Sentinel nodes showed elevated amount of all cell types studied in comparison to non-sentinel nodes.
Metastatic SLNs had higher density of OX40+ lymphocytes compared to tumor-negative nodes, while no significant
difference was observed in the case of the other cell types studied. In patients with positive sentinel node status,
high amount of FOXP3+ cells in SLNs was associated with shorter progression-free (P = 0.0011) and overall survival
(P = 0.0014), while no significant correlation was found in the case of sentinel-negative patients. The density of
OX40+, CD123+ or DC-LAMP+ cells did not show significant association with the outcome of the disease.
Conclusions: Taken together, our results are compatible with the hypothesis of functional competence of sentinel
lymph nodes based on the prevalence of the studied immune cells. The density of FOXP3+ lymphocytes showed
association with progression and survival in patients with positive SLN status, while the other immune markers
studied did not prove of prognostic importance. These results, together with our previous findings on the
prognostic value of activated T cells and mature DCs infiltrating primary melanomas, suggest that immune
activation-associated markers in the primary tumor may have a higher impact than those in SLNs on the prognosis
of the patients. On the other hand, FOXP3+ cell density in SLNs, but not in the primary tumor, was found predictive
of disease outcome in melanoma patients.
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The sentinel lymph node (SLN), the first proximal
lymph node draining a primary tumor, is a preferential
site of early metastasis. Identification, removal and
pathologic examination of SLNs are part of the routine
surgical management in the case of melanoma and
breast cancer. In melanoma, pathologic determination of
the extent of SLN involvement provides a powerful
prognostic indicator of survival [1].
Besides its importance in staging and prognosis, the sen-
tinel node is also a privileged site of T-cell priming, and
may thus be an appropriate target for investigating cell
types and mechanisms involved in antitumor immune
reactions. Previous studies have found evidence for
alterations in immunoreactivity of SLNs compared either
to non-sentinel lymph nodes (NSLNs) from the same pa-
tient cohort [2-7] or to control lymph nodes from non-
tumor patients [7-10]. The results of these investigations,
however, are somewhat controversial (Table 1). While
some reports on melanoma and breast cancer suggested
that sentinel lymph nodes are immune suppressed
compared to non-sentinel nodes, containing lower num-
ber of DCs and T lymphocytes [2,3,7], other studies on
various tumor types did not find such differences [4-6,11].
Similar controversy exists when SLNs are compared to
non-tumor control lymph nodes [7-10,12].
Comparison of immune parameters in tumor-positive
vs. -negative SLNs also yielded somewhat ambiguous
data (Table 1). Generally, sentinel nodes with metastases
were demonstrated to contain more FOXP3+ cells than
tumor-free ones in melanoma, breast or gastric cancer
[8,13-15]. Other T-cell subsets were less frequently stud-
ied but were mostly found in similar amount in positive
and negative SLNs. Data concerning dendritic cells infil-
trating various cancers were less conclusive, with some
studies showing lower amount of certain DC subtypes in
tumor-containing than in tumor-free SLNs [9,12] while
others reporting no such difference [10,11,13].
While the detection of metastases in SLN has an import-
ant role in determining the prognosis of patients in the
case of several tumor types, the potential of prognostic ap-
plication of the examination of immune status of these
nodes is largely unexploited. A report by Cochran et al.
demonstrated the prognostic role of DC density in melan-
oma SLNs [16], while data from studies by Elliott and
coworkers indicated an association between survival of mel-
anoma patients and the density of DC-LAMP+ mature den-
dritic cells in metastasis-containing SLNs [17]. On the
other hand, according to Kohrt et al., DC and CD4+ T cell
populations in axillary lymph nodes, but not in SLNs,
predicted disease-free survival in breast cancer [7]. Accu-
mulation of FOXP3+ regulatory T cells in SLNs was
demonstrated to be associated with poor prognosis in
breast and gastric cancer as well as in melanoma [13,14,18].Furthermore, the presence of IDO+ cells in SLNs of melan-
oma patients correlated with unfavorable outcome [14,19].
Taken together, results on the immune competence of
SLNs are controversial; while some studies suggest that
these lymph nodes are immune deficient, “preconditioned”
to host metastases by tolerogenic cells or suppressive
factors deriving from the primary tumor [2,3,7,10], others
seem to indicate that, on the contrary, SLNs are not
suppressed, or may even be in an activated state due to
stimulation by tumor antigens [4-6,9,11,12]. The presence
of metastatic tumor in SLNs seems to be associated with
elevated amount of regulatory T cells in several tumor types
[8,13-15], which may indicate a state of immune suppres-
sion. However, results concerning other immune cell types
are equivocal [9-13,15,20]. Few reports have addressed the
prognostic potential of determining the immune status of
SLNs [7,13,14,16-18] or associations of immune cell dens-
ities in SLNs with clinicopathologic factors [13,14,18].
Our previous studies investigating the prevalence of
immune cell types in primary cutaneous melanomas
identified infiltration by T lymphocytes expressing the
activation markers CD25 and OX40, as well as the den-
sity of DC-LAMP+ mature DCs as prognostic factors
[21,22]. These results suggest that the presence of activated
Tcells and antigen presenting DCs at the primary site could
be a marker of a functional immune response against me-
lanoma progression and influence the outcome of the dis-
ease. On the other hand, the density of FOXP3+ regulatory
T lymphocytes in primary melanomas did not prove of
prognostic significance [23]. In the present study we
examined the prevalence of several immune cell types:
OX40+ activated T lymphocytes, FOXP3+ regulatory Tcells,
DC-LAMP+ mature DCs and CD123+ plasmacytoid DCs in
sentinel lymph nodes of melanoma patients. In selecting
the markers to be studied we intended to include cell types
the prevalence of which has proved of prognostic value in
earlier studies on primary melanoma or sentinel nodes.
The main objectives of the study were i) to evaluate
the immune status of SLNs in comparison to non-
sentinel nodes, examining markers associated with im-
mune activation (the presence of mature DCs and
activated T cells) or those generally considered as signs
of immune suppression (pDCs and Treg cells), and ii) to
determine whether these immune parameters are pre-
dictive of the outcome of the disease in terms of tumor
progression and patients’ survival.
Methods
Patients and samples
Archival tissue samples were obtained from 60 patients with
cutaneous melanoma of >1 mm thickness who underwent
sentinel lymph node dissection at the National Institute of
Oncology, Budapest, between 1999 and 2001. The study was
approved by the ethics committee of the institute and by the
Table 1 Prevalence of immune cell types in sentinel vs. non-sentinel nodes and in positive vs. negative SLNs
Study (reference) Tumor Number
of
Number
of
Dendritic
cells
Mature
DCs
Plasmacytoid
DCs
T cells Regulatory T cells
type patients
(SLNs)
+ / -
SLNs
SLN vs.
NSLN
+ vs. -
SLN
SLN vs.
NSLN
+ vs. -
SLN
SLN vs.
NSLN
+ vs. -
SLN
SLN vs.
NSLN
+ vs. -
SLN
SLN vs.
NSLN
+ vs. -
SLN
Compared to NSLNs of the same patient cohort
Cochran et al. 2001 [3] melanoma 11 (21) 10 / 11 lower NT NT NT NT NT NT NT NT NT
Botella-Estrada et al. 2005 [4] melanoma 10 (17) 1 / 16 higher NT no diff. NT NT NT NT NT NT NT
Gerlini et al. 2007 [20] melanoma 27 (39) 8 / 31 NT NT NT NT NT higher NT NT NT NT
Speeckaert et al. 2011 [14] melanoma 116 (116) 26 / 90 NT NT NT NT NT NT NT NT NT higher
Ma et al. 2012 [15] melanoma 84 (84) 31 / 53 NT lower NT higher NT NT NT NT NT higher
Huang et al. 2000 [2]2 breast cc. 21 (21) not spec. lower NT lower NT NT NT lower NT NT NT
Kohrt et al. 2005 [7]2 breast cc. 29 (29) 29 / 0 lower NT NT NT NT NT lower (CD4+) NT NT NT
Bembenek et al. 2008 [6] breast cc. 79 (114) 51 / 283 NT NT higher NT NT NT NT NT NT NT
Ishigami et al. 2003 [11] gastric cc. 27 (27) 8 / 19 no diff. no diff. NT NT NT NT no diff. no diff. NT NT
Lee et al. 2011 [13] gastric cc. 64 (64) 45 / 193 NT NT NT no diff. NT NT NT no diff. NT higher
Sakakura et al. 2005 [5] oral cc. 12 (41) 0 / 41 higher NT no diff. NT NT NT NT NT NT NT
Compared to non-tumor control nodes
Mansfield et al. 2011 [10] melanoma 20 (20) 8 / 12 NT NT lower no diff. no diff. no diff. lower (CD8+) no diff. no diff. no diff.
Poindexter et al. 2004 [12] breast cc. 50 (50) 25 / 25 no diff. no diff. no diff. lower NT NT NT NT NT NT
Mansfield et al. 2009, 2011 [8,9] breast cc. 47 (47) 36 / 11 no diff. no diff. higher lower no diff. no diff. higher (CD8+) no diff. no diff. higher
Columns SLN vs. NSLN: comparison of negative SLNs to negative NSLNs or controls (except in studies [2] and [7]); columns + vs. - SLN: comparison of positive to negative SLNs.
1SLNs and NSLNs of unspecified status were compared; 2positive SLNs were compared to mixed (+ and -) NSLNs; also compared to non-tumor controls, with similar results
3number of patients with + / - SLN status; NT: not tested; no diff.; no difference; not spec.: not specified.
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Table 2 Patient and tumor characteristics
Patient group All patients SLN-negative SLN-positive
Age – median (range) 54 (27–79) 54 (27–79) 54 (27–76)
Sex
Male 27 16 11
Female 33 19 14
Tumor thickness (mm)
1.01–2.0 29 21 8
2.01–4.0 20 8 12
>4.0 11 6 5
Tumor site
Extremities 31 18 13
Trunk 29 17 12
Histologic type
SSM 37 24 13
NM 19 10 9
ALM 4 1 3
Ulceration
Absent 37 26 11
Present 20 9 11
Unknown 3 - 3
Progression in 5 years
No 38 28 10
Yes 22 7 15
5-year survival (%) 43/60 (72) 31/35 (89) 12/25 (48)
SSM, superficial spreading melanoma; NM, nodular melanoma; ALM, acral
lentiginous melanoma.
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TUKEB). Patients did not receive any anticancer treatment
prior to surgery. SLN dissection was performed at the time
of the removal of the primary tumor in the majority of cases
(n = 47), or 2 to 10 weeks (median: 4 weeks) later in patients
whose primary melanoma had been operated in other
institutions (n = 13). SLN biopsy was carried out using
double labeling (99mTc-albumin and patent blue dye) as pre-
viously described [24,25]. Histological evaluation of sentinel
lymph nodes was performed on serial sections using
hematoxylin-eosin staining and immunohistochemical label-
ing for MART-1/Melan-A.
In 38 cases there was no tumor progression detected
in the follow-up period of 5 years; 28 of these patients
presented with negative SLNs, 4 with isolated tumor
cells or metastases <0.1 mm in diameter, 3 with metasta-
ses of 0.1–1.0 mm and 3 with metastases >1.0 mm
according to the maximum diameter of the largest le-
sion. In 22 patients progression involving various organs
was observed; 7 of them had tumor-free SLNs while 15
had positive nodes: 6 with metastases of 0.1–1.0 mm
and 9 with metastases >1.0 mm in at least one of the
SLNs examined. A total of 100 sentinel nodes (69
tumor-free and 31 tumor-positive) of these 60 patients
were analyzed. Clinical and pathological characteristics
are summarized in Table 2. Surviving patients had
follow-up data for at least 5 years; none of the patients
died of melanoma-unrelated causes within 5 years. Of
the 22 patients showing disease progression, 17 had died
by the end of the 5-year follow-up period while 5 patients
were alive with (n = 3) or without (n = 2) disease.
For a subset of the patients, lymph node samples from
block dissection, performed because of positive SLN sta-
tus 2 to 7 weeks (median: 3 weeks) following SLN bi-
opsy, were also available (37 lymph nodes, two
metastatic and 35 tumor-negative, from 7 patients).
Immunohistochemical detection of immune cell types
Three-μm sections cut from formalin-fixed, paraffin-
embedded samples were used. Immunohistochemistry
was performed as described earlier [21-23], using mono-
clonal antibodies against FOXP3 (236A/E7; Abcam Inc.,
Cambridge, MA), OX40 (CD134) (BD Biosciences Eastern
Europe, Heidelberg, Germany), CD123 (BD Biosciences),
and DC-LAMP (CD208) (Beckman Coulter-Immunotech,
Marseille, France), followed by polymer-conjugated sec-
ondary antibody (SS™ One-Step Polymer-HRP IHC De-
tection System, BioGenex, Fremont, CA), visualization
with 3-amino-9-ethylcarbazole (Vector Laboratories, Inc.,
Burlingame, CA), and counterstaining with hematoxylin.
Evaluation of the immune reactions
Slides were examined using a graticule of 10x10 squares,
calibrated as 0.25 mm2 at 200× magnification. Countingwas performed independently by two investigators, both
blinded to the clinical information, and the mean value
of their separate counts was used for the analysis.
Sections were scanned at low magnification, and 5 areas
with the highest density of positive cells (hot spots) were
counted at 400x magnification. Staining for OX40 and
CD123 could not be evaluated in one case each. In the
case of patients with more than one SLN available, the
mean labeled cell densities of all SLNs studied were also
registered. For each marker, cutoff levels were set up
based on the median of the given variable in the whole
patient group, with minor adjustment for better discrim-
inating power in the case of FOXP3, OX40 and CD123
(1900, 73, 480 and 936 cells/mm2 for FOXP3, OX40,
CD123 and DC-LAMP, respectively), and the proportion
of patients with a mean cell density higher than the
cutoff level was determined.
Statistical analysis
Comparisons between cell densities in different tumor
groups was made using the Mann–Whitney U test and
Kruskal-Wallis test, while χ2 test was used for comparing
a b
c d
Figure 1 FOXP3+ (a), OX40+ (b), DC-LAMP+ (c) and CD123+ cells (d) in melanoma sentinel lymph nodes (bars: 20 μm).
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cells. Analysis of survival was performed by the Kaplan-
Meier method, and the statistical analysis was carried
out by the Mantel-Cox test. Univariate and multivariate
Cox regression analyses were performed using mean im-
mune cell densities, Breslow index and patients’ age as
continuous variables, as well as location, histological
type and ulceration of the tumors, SLN status and pa-
tient gender as categorical variables. All statistics were
calculated using the BMDP Statistical Software Pack.
Results
Expression of the studied markers in sentinel lymph
nodes
Using immunohistochemical labeling with antibodies
against marker antigens, we found varying amount of
the four immune cell types studied in the lymph node
samples. The majority of lymphocytes exhibiting nuclear
staining for FOXP3, as well as those showing mem-
brane staining for OX40, were distributed diffusely in
the T-cell areas of the paracortex (Figure 1a,b). Mature
dendritic cells, showing the characteristic juxtanuclear
dot-like staining for the DC-LAMP marker, were also
located predominantly in the paracortical regions of
lymph nodes, surrounding T-cell areas (Figure 1c).
CD123+ plasmacytoid DCs appeared either scattered or
as aggregates in the paracortex, mostly around high
endothelial venules, also showing positive staining for
CD123 (Figure 1d). In some of the metastatic nodes, es-
pecially in cases with large tumor deposits, localization
of OX40+ lymphocytes as well as DC-LAMP+ dendriticcells in the vicinity of metastases could be seen, occa-
sionally infiltrating the tumors. This was less frequently
observed in the case of FOXP3+ lymphocytes or CD123+
pDCs. Quantitative analysis of immunohistochemistry
results, evaluating 5 areas with the highest density of
positive cells at high magnification in each sample,
revealed that FOXP3+ lymphocytes were the most abun-
dant (mean ± SD, 2003 ± 720 cells/mm2), followed by
DC-LAMP+ mature dendritic cells (938 ± 280 cells/mm2)
and CD123+ pDCs (650 ± 434 cells/mm2), while OX40+
activated T lymphocytes were the least numerous (100 ±
68 cells/mm2). No correlation was found between density
values of the different cell types.
Comparison of immune cell densities in sentinel vs. non-
sentinel nodes and in metastatic vs. tumor-free SLNs
For a subset of the above patients, lymph node samples
from block dissection, performed because of positive
SLN status, were also available (37 lymph nodes from 7
patients). Compared to SLNs, these nodes showed
lower density of cells labeled for FOXP3, OX40 and
DC-LAMP, while a difference of borderline significance
was noted in the number of CD123+ plasmacytoid DCs
(Figure 2a). The same trends, although with less signifi-
cant differences, were observed when only tumor-free
lymph nodes of the SLN (n = 69) and NSLN group
(n = 35) were considered (Figure 2b). In these studies
sentinel nodes from all patients (35 SLN-negative and
25 SLN-positive) vs. non-sentinel nodes from 7 patients
(all SLN-positive) were evaluated. Similar results were
obtained when sentinel nodes from only the SLN-
Figure 2 Density of immune cell types a) in non-sentinel (n = 37) and sentinel (n = 100) lymph nodes; b) in tumor-negative NSLNs
(n = 35), and tumor-negative (n = 69) or -positive (n = 31) SLNs. Dots represent individual values; horizontal bars are medians.
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shown). Moreover, individual comparison of mean dens-
ities of labeled cells in SLNs and NSLNs of the 7 patients
with available NSLN samples (Table 3) shows that in the
majority of patients SLN values are higher or comparable
to NSLN values for all immune cell types.
Comparison of sentinel lymph nodes diagnosed as
tumor-positive (n = 31) or -negative (n = 69) according
to histological and immunohistochemical analysisshowed higher mean density of OX40+ lymphocytes in
positive nodes compared to negative ones, while no sig-
nificant difference was observed in the amount of the
other cell types studied (Figure 2b).
Associations of immune cell densities in sentinel nodes
with clinicopathologic factors
Evaluating the mean labeled cell densities in SLNs, no
associations with patient or tumor parameters (Breslow
Table 3 Comparison of mean immune cell densities in
SLNs and NSLNs for 7 patients with available SLN and
NSLN samples (mean density values for lymph nodes
from each patient; cells/mm2)
Patient
no.
FOXP3 OX40 CD123 DC-LAMP
SLN NSLN SLN NSLN SLN NSLN SLN NSLN
1 1958 957 193 65 232 280 818 660
2 1925 1477 119 192 1450 621 957 648
3 2205 1060 15 60 222 214 573 1038
4 1562 1450 117 29 938 242 592 657
5 2123 2086 245 192 1154 566 1059 384
6 2814 1747 61 33 244 225 925 744
7 1768 1633 54 60 395 1040 1171 989
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tumors, patients’ age and gender) were found for any of
the immune cell markers studied. Analysis of the propor-
tion of patients with mean cell densities higher than the
cutoff level, with respect to the above parameters, revealed
no association for any of these parameters either, except
an elevated ratio of cases with high mean CD123+ cell
density in younger patients (Additional file 1).
Analysis of disease progression and survival according to
immune cell densities in the sentinel nodes
Kaplan-Meier analysis of survival according to the mean
density of FOXP3+ lymphocytes in SLNs revealed that
high number of these cells was associated with signifi-
cantly shorter progression-free and overall survival
(Figure 3a,b). Analyzing cases separately for patients with
positive and negative SLN status revealed that the above
findings were entirely due to the prominent differences
observed in the subgroup of sentinel-positive patients
(Figure 3c,d), while no such variance could be seen in the
sentinel-negative patient group (Figure 3e,f). The amount
of the other immune cell types studied did not show sig-
nificant correlation with survival.
The potential prognostic effect of immune cell densities
evaluated as continuous variables, together with other
clinicopathologic factors (thickness, location, histological
type and ulceration of the primary tumor, SLN status, pa-
tient age and gender), was also evaluated using Cox’s pro-
portional hazards model. In univariate analysis of all cases,
ulceration, Breslow index, SLN status and histological type
were found significantly associated with both progression-
free and overall survival (P = 0.000, P = 0.001, P = 0.003
and P = 0.033 for PFS; P = 0.000, P = 0.000, P = 0.002 and
P = 0.028 for OS, respectively). Multivariate analysis iden-
tified ulceration, Breslow index, SLN status and patient
gender as significant independent predictors of survival
(P = 0.000, P = 0.005, P = 0.005 and P = 0.017 for PFS;
P = 0.000, P = 0.005, P = 0.016 and P = 0.008 for OS,respectively). The amount of the studied cell types in
SLNs did not prove predictive of either progression-
free or overall survival. Analyzing only patients with
positive SLN status, however, yielded significant or
near significant associations between mean FOXP3+
cell density and survival (univariate analysis: P = 0.054
and P = 0.038; multivariate analysis: P = 0.046 and
0.069 for PFS and OS, respectively), with ulceration,
Breslow index and patient gender as other significant
covariates. In the case of SLN-negative patients, only
histological type and ulceration of the tumor showed
association with progression-free and overall survival.
Discussion
In this retrospective study we determined the density of
several immune cell types: OX40+ activated T
lymphocytes, FOXP3+ regulatory T cells, DC-LAMP+
mature dendritic cells and CD123+ plasmacytoid DCs in
sentinel lymph nodes of patients with malignant melan-
oma. Density values of each cell type in SLNs vs. lymph
nodes obtained from block dissection, as well as those in
tumor-free vs. metastatic SLNs were compared. Further-
more, results were evaluated with regard to associations
with patient and tumor parameters and the outcome of
the disease.
In our cohort of 100 sentinel nodes, FOXP3+ lymphocytes
proved the most abundant cell type, greatly outnumbering
OX40+ activated T cells. This finding could be considered a
sign of immunosuppression. However, OX40 is a very
specialized marker expressed primarily by recently activated
CD4+ T lymphocytes showing preferential accumulation at
tumor sites in cancer patients and is thought to represent
tumor antigen specific T cells [26,27]. Since it is not a gen-
eral marker of all activated T cells, the expression of OX40
is expected to be restricted. Moreover, most immune cell
types studied were present in higher amount in the sentinel
nodes compared to 37 non-sentinel nodes from a subset of
the patients, not only FOXP3+ Tregs but also OX40+
activated Tcells and DC-LAMP+ mature DCs.
Our results were mainly based on interindividual
comparisons of labeled cells in SLNs vs. NSLNs. We did
not perform statistical analysis comparing SLN-NSLN
pairs of the same patients because of the low number of
cases with available NSLN samples. Moreover, since it was
a retrospective study, we did not have access to non-
sentinel nodes of sentinel-negative patients. On the other
hand, in our study, similarly to others comparing sentinel
and non-sentinel nodes from the same patients, NSLNs
derived from the same lymph node basin as the SLN.
Therefore, they were likely also affected by the primary
tumor albeit to a lesser degree than the SLN. Nevertheless,
our results indicate a state of functional activity in the sen-
tinel lymph nodes, or at least no unambiguous signs of
immune suppression compared to NSLNs.
Figure 3 Kaplan-Meier curves of progression-free (a,c,e) and overall survival (b,d,f) for melanoma patients (a,b: all patients; c,d:
positive SLN status; e,f: negative SLN status) subdivided according to mean SLN FOXP3+ cell density.
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logically competent or suppressed is a matter of debate,
with no consensus reached yet. According to Cochran’s
group, SLNs draining melanoma and breast cancer show
evidence of immunosuppression, with lower number of
paracortical dendritic cells (DCs) and lower expression
of costimulatory molecules compared to NSLNs [2,3].
Other studies examining various DC markers, however,
found either higher amount of DCs in SLNs or no differ-
ence from NSLNs or control lymph nodes in melanoma,
breast, gastric or oral cancers [4-6,9-12] (Table 1). One
reason for this discrepancy could be the relatively small
sample size in many of the studies comparing SLNs and
NSLNs, hampering the drawing of reliable conclusions.Also, while some of these investigations evaluated meta-
static and tumor-free SLNs separately, others did not
make such distinction which makes the results difficult
to compare. Nevertheless, most comparative studies
mentioned above, including the few involving higher
case numbers, seem to indicate that sentinel lymph
nodes are not suppressed (Table 1). It should be noted,
however, that signs of immune activation and those of
dysfunction can be detected at the same time in some of
the studies, including ours. Moreover, the balance of ac-
tivation and suppression most probably changes with
time, parallel to tumor progression.
Analysis of our results according to tumor positivity of
sentinel nodes resulted in no significant difference in the
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FOXP3, in contrast to some [14,15], but not all [10] other
studies on melanoma SLNs (Table 1). The reason for this
discrepancy is not known, but may partly be explained by
methodological differences. On the other hand, in our
present study positive nodes contained higher amount of
OX40+ activated T lymphocytes compared to negative
ones, which may be related to in situ activation of T cells
recognizing tumor antigens. In accordance with this
finding, a previous report on axillary lymph nodes of
breast cancer patients revealed preferential accumulation
of OX40+ cells only in positive nodes [27].
We did not find significant difference between meta-
static and tumor-free SLNs in the density of DC-LAMP+
mature dendritic cells or CD123+ plasmacytoid DCs.
Results concerning dendritic cell subtypes in SLNs are
contradictory in the case of melanoma and other tumor
types as well (Table 1). A recent paper described
decreased number of CD11c+ dendritic cells but elevated
amount of CD86+ mature DCs in positive compared to
negative sentinel lymph nodes in melanoma [15]. In
breast cancer, mature DCs detected by the CD83 or
DC-LAMP marker were present in lower amount in
tumor-positive SLNs compared to tumor-negative ones
while the density of DCs stained for CD1a was similar
[9,12]. On the other hand, there was no difference in the
number of either S100+ or DC-LAMP+ DCs in metastatic
vs. tumor-free SLNs in gastric carcinoma [11,13]. The
prevalence of plasmacytoid DCs (pDCs) was found more
prominent in tumor-containing SLNs in one study on
melanoma [20] while no difference was detected between
metastasis-positive and -negative SLNs in another [10]
or in breast cancer [9].
In our patient cohort, density of DC-LAMP+ mature
DCs, CD123+ plasmacytoid DCs and OX40+ activated
T cells in sentinel nodes did not show significant associ-
ation with disease progression or survival. No previous
studies have been reported on a potential prognostic
effect of the amount of pDCs or activated T cells in
sentinel nodes in any tumor types. In a study on
tumor-positive SLNs in melanoma, the accumulation
of DC-LAMP+ DCs was shown to have a statistically sig-
nificant but weak impact on survival, and did not prove
independent prognostic factor [17]. On the other hand,
infiltration of primary melanomas by DC-LAMP+ mature
dendritic cells and OX40+ activated T cells proved strong
independent predictors of survival according to our pre-
vious studies [21,22]. The above findings on the more
prominent prognostic effect of these cell types at the site
of the primary melanoma may indicate the importance of
immune cells residing in the primary tumor in the devel-
opment of antitumor immune response.
On the other hand, the amount of FOXP3+ cells infil-
trating primary melanomas did not show associationwith the outcome of the disease according to our previ-
ous study [23]. In contrast to these results, our present
findings indicate that quantification of FOXP3+ cells in
SLNs may provide information with prognostic impact.
High mean density of these cells was associated with sig-
nificantly shorter progression-free and overall survival. A
novel, intriguing finding of our study is that high density
of FOXP3+ cells in sentinel nodes was associated with
disease progression and shorter survival only in cases
with positive SLN status. Moreover, univariate and
multivariate Cox regression analyses evaluating mean
cell density values as continuous variables showed
associations with survival only in the case of positive
SLN status and not in patients with negative SLNs or in
the whole patient group. A recent study by Speeckaert
et al., not evaluating cases with different SLN status
separately, also could not prove the independent prog-
nostic effect of FOXP3+ cells in sentinel nodes of melan-
oma patients [14]. Although the sentinel-negative but
progressing cases in our study represented a minority of
the samples (7 patients), which in theory might have
influenced the result of such comparisons, differences in
PFS and OS were much larger in the SLN-positive group
compared to those in the whole cohort. These results in-
dicate that Tregs may exert their suppressor function
more efficiently in metastatic nodes, at least at a degree
that would be reflected in influencing the outcome of
the disease. Reasons for this difference could include the
relative abundance of Tregs in positive nodes as
suggested by some studies [8,13-15], or an elevated ac-
tivity of tumor-specific immune reactions in the pres-
ence of tumor antigens.
Priming of antitumor T-cell responses is generally
believed to take place primarily in draining lymph nodes
via cross presentation of tumor antigens by dendritic
cells capturing antigens at the primary tumor site and
migrating to lymph nodes. However, in experimental
models direct priming of T lymphocytes by tumor cells
in the lymph nodes has been described [28,29]. In mel-
anoma patients, precursor frequency of peripheral blood
CD8+ T cells recognizing melanocyte differentiation
antigen epitopes was found increased in stage III and IV
vs. stage I and II, indicating the importance of the devel-
opment of lymph node metastases in triggering T-cell
mediated antitumor immunity [30]. On the other hand,
it has also been shown that T-cell activation by dendritic
cells may occur extranodally, at tumor sites [31]. In ac-
cordance with this finding, a study analyzing T-cell
clonotypes revealed that the majority of T cells in
tumor-negative SLNs are not clonally expanded [32], in
contrast to primary melanomas and metastatic lesions
showing the presence of multiple clonotypic TCR
transcripts [32,33]. In the light of these data, the results
of our present and previous studies could be interpreted
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markers in tumoral compartments of melanoma
patients, both in the primary tumor and in metastatic
sentinel lymph nodes.
Conclusion
We have shown that the prevalence of the studied im-
mune cells in sentinel lymph nodes is higher compared
to non-sentinel ones, which is compatible with the hy-
pothesis of functional competence of SLNs, supported
by the majority of previous studies. Some of the changes
seem to occur before the arrival of tumor cells, while the
amount of OX40+ activated T cells was found elevated
in metastatic SLNs. The density of FOXP3+ lymphocytes
showed association with disease progression and shorter
survival in sentinel-positive patients, while the other im-
mune cell types studied did not prove of prognostic sig-
nificance. These results, together with our previous
findings on the prognostic value of activated T cells and
mature DCs infiltrating primary melanomas, suggest
that immune activation-associated markers in the pri-
mary tumor may have a higher impact than those in
SLNs on the prognosis of the patients. On the other
hand, FOXP3+ cell density in metastatic SLNs, but not
in tumor-negative ones or in primary melanomas, was
found predictive of the outcome of the disease.
Our results were based on a retrospective analysis of
lymph node samples of a sizeable group of melanoma
patients, however, evaluating sentinel-positive and nega-
tive cases separately according to disease progression or
survival yielded more limited case numbers. To obtain a
more complete view on the immune characteristics of
these lymph nodes and on the prognostic value of these
immune markers, prospective studies on larger patient
cohorts are warranted.
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